New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K – ONCOGENEX PHARMACEUTICALS, INC. (0000949858) (Filer)





A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K – ONCOGENEX PHARMACEUTICALS, INC. (0000949858) (Filer)
Filed: 2016-08-22 AccNo: 0001193125-16-687677 Size: 15 KB

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Filing Date: 2016-08-22T17:00:32-04:00

This is a breaking news story. You can access the complete current report through the SEC’s Edgar system: http://www.sec.gov/Archives/edgar/data/949858/000119312516687677/0001193125-16-687677-index.htm